Our studies support the use of agents that disrupt the cross talk between malignant cells and the stroma and suggest that CXCR4 inhibitors may have a potential therapeutic role in pancreatic cancer that should be tested in future studies. Here, CXCR4 is linked to pancreatic neoplasm.